Singula Phase 0.1 Primary Care Pilot
Validation of an Artificial Intelligence (AI)-Powered Clinical Decision Support System for Anxiety and Depression in Primary Care Settings
This prospective, single-arm, observational pilot study evaluates a clinical decision support system developed by Singula Health for use in primary care. Adult patients complete a self-report assessment before a routine primary care visit. The system uses the responses to generate a clinician-facing Companion Brief that summarizes relevant information for the treating clinician. Each Companion Brief is reviewed by the Principal Investigator before it is provided to the clinician. The study will evaluate whether the system can reliably generate and deliver the Companion Briefs, whether clinicians find the Briefs useful and acceptable, and whether patients can successfully complete and accept the pre-visit assessment.
Przegląd badań
Status
Szczegółowy opis
The Singula clinical decision support system is designed to organize information collected from a patient before a routine primary care visit into a structured Companion Brief for the treating clinician. The pre-visit assessment includes validated screening measures and structured questions addressing behavioral health symptoms and other factors relevant to the patient's clinical context. After a patient completes the assessment, an automated software pipeline processes the responses and generates a draft Companion Brief. The Principal Investigator reviews each Artificial Intelligence (AI)-generated Brief for clinical accuracy, appropriate safety language, and potential errors before it is released to the treating clinician. The treating clinician receives the reviewed Brief before the patient's routine primary care visit and retains full independent authority over clinical assessment and decision-making. The Companion Brief is informational and does not direct treatment. This Phase 0.1 pilot is intended primarily to characterize the feasibility and operational performance of this workflow in real-world primary care. The study will examine successful generation and delivery of Companion Briefs, pipeline performance, clinician feedback regarding the utility and acceptability of the Briefs, patient completion of the pre-visit assessment, and errors or other operational issues identified during the pilot. Findings from this study are intended to inform subsequent technical, operational, and clinical development of the system.
Typ studiów
Zapisy (Szacowany)
Kontakty i lokalizacje
Kontakt w sprawie studiów
- Nazwa: Marc S Lener, MD
- Numer telefonu: (240) 389-2381
- E-mail: marc.lener@singulahealth.com
Lokalizacje studiów
-
-
New York
-
Brentwood, New York, Stany Zjednoczone, 11717
- Zakończony
- Morris Medical Office
-
Mount Kisco, New York, Stany Zjednoczone, 10549
- Rekrutacyjny
- WestDocs Concierge
-
Kontakt:
- Lisa Youkeles, MD
- Numer telefonu: 914-218-3838
- E-mail: general@westdocsconcierge.com
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Metoda próbkowania
Badana populacja
Adults aged 18 years or older presenting for a routine, non-urgent primary care visit at a participating independent primary care practice. Eligible patients complete a pre-visit electronic informed consent and self-report assessment (Survey 0.1) on a personal device prior to their scheduled visit.
Opis
Inclusion Criteria:
- Adult, aged 18 years or older at the time of consent.
- Scheduled for a routine, non-urgent primary care visit at a participating practice.
- Able to read and understand English at a level sufficient to complete the electronic informed consent and Survey 0.1 independently.
- Has personal-device access to complete the survey (smartphone, tablet, or computer with internet).
- Capable of providing informed consent.
Exclusion Criteria:
- Non-English-speaking, defined as inability to read English at a level sufficient to complete electronic informed consent and the survey independently.
- Visually impaired to a degree that prevents independent reading of an electronic consent form on a personal device, without specialized assistive technology beyond standard mobile-device accessibility features.
- Unable to read for any reason (literacy, cognitive impairment, or other).
- Presenting with an acute psychiatric emergency or in acute crisis at the time of the scheduled visit, as identified by clinic staff during routine check-in.
- Patient is a known minor at the time of scheduling (under 18 years).
- Patient or clinician declines participation.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Modele obserwacyjne: COHORT
- Perspektywy czasowe: PROSPECTIVE
Kohorty i interwencje
Grupa / Kohorta |
|---|
|
Primary Care Patient Cohort
Adult primary care patients evaluated during routine clinical care using the Singula Artificial Intelligence (AI)-powered clinical decision support system for assessment of anxiety and depression. Participants are included in a single observational cohort; no study-assigned intervention is administered. |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Successful Production and Delivery of the Companion Brief
Ramy czasowe: Up to 7 days
|
Proportion of enrolled patient cases for which an Artificial Intelligence (AI)-generated Companion Brief is successfully produced, reviewed by the Principal Investigator, and delivered to the treating clinician prior to the patient's scheduled visit. |
Up to 7 days
|
|
Clinician-Rated Overall Clinical Utility of the Companion Brief
Ramy czasowe: Periodic feedback during active enrollment, approximately 30 to 90 days
|
Clinician-rated overall clinical utility of the Companion Brief, captured on the periodic batched feedback survey using a 5-point Likert scale. Target: ≥70% of feedback batches indicating overall utility of "useful" or "very useful" across the cases covered in each batch. |
Periodic feedback during active enrollment, approximately 30 to 90 days
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Survey 0.1 Completion Rate
Ramy czasowe: Up to 7 days
|
Completion rate of Survey 0.1 among consented patient participants |
Up to 7 days
|
|
Pipeline End-to-End Latency
Ramy czasowe: Up to 72 hours
|
End-to-end latency from Survey 0.1 submission to availability of the generated Companion Brief in storage. |
Up to 72 hours
|
|
Principal Investigator Corrections to Large Language Model (LLM)-Generated Reports
Ramy czasowe: Up to 7 days
|
Number and category of Principal Investigator corrections to Large Language Model (LLM)-Generated Companion Briefs, categorized as clinical accuracy, safety language, formatting, or hallucination. |
Up to 7 days
|
|
Number of Safety-Flag Triggers Generated by the Clinical Decision Support System
Ramy czasowe: Up to 8 days
|
Total number of safety-flag triggers generated by the clinical decision support system during the study period. Safety-flag triggers will be classified by risk level (Critical or High) for descriptive reporting. |
Up to 8 days
|
|
Number of Safety-Flag Triggers by Documented Disposition
Ramy czasowe: Up to 8 days
|
Number of safety-flag triggers by documented disposition category following Principal Investigator review and clinician notification. |
Up to 8 days
|
|
Clinician-Rated Most Useful Companion Brief Section
Ramy czasowe: Periodic feedback during active enrollment, approximately 30 to 90 days
|
Clinician identification of the most useful Companion Brief section across cases included in each feedback batch. |
Periodic feedback during active enrollment, approximately 30 to 90 days
|
|
Number of Feedback Batches With Clinician-Reported Influence on Clinical Decision-Making, Measured by the Singula Clinician Feedback Survey
Ramy czasowe: Periodic feedback during active enrollment, approximately 30 to 90 days
|
Clinician-reported influence of Companion Briefs on clinical decision-making will be assessed using the Singula Clinician Feedback Survey. For each feedback batch, clinicians will indicate whether any Companion Brief in the batch period influenced a clinical decision. The outcome will be reported as the number of feedback batches in which an influence on clinical decision-making was reported. |
Periodic feedback during active enrollment, approximately 30 to 90 days
|
|
Clinician-Reported Willingness to Continue Using the Companion Brief, Measured by the Singula Clinician Feedback Survey
Ramy czasowe: Periodic feedback during active enrollment, approximately 30 to 90 days
|
Clinician-reported willingness to continue using the Companion Brief system will be assessed using the Singula Clinician Feedback Survey. Responses will be summarized across clinician feedback collected during the study period. |
Periodic feedback during active enrollment, approximately 30 to 90 days
|
|
Patient Survey Dropout and Skip Patterns
Ramy czasowe: Up to 7 days
|
Patient-side dropout and question-skipping patterns during completion of Survey 0.1. |
Up to 7 days
|
Współpracownicy i badacze
Sponsor
Śledczy
- Główny śledczy: Marc S Lener, MD, Singula Health, Inc.
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- SINGULA-CDSS-PCP-0.1
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
Individual participant data will not be shared with other researchers. External use of study findings will be limited to aggregate, de-identified data. Individual participant data, individual Companion Briefs, and individual survey responses will not be used externally. De-identified analytic data may be retained by Singula Health, Inc. for internal product development, regulatory documentation, and internal research and quality improvement.
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .